Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).-论文-万方医学网

作者： Javier,Puente ^[1] ; Aranzazu,González-Del-Alba ^[2] ; Núria,Sala-Gonzalez ^[3] ; María José,Méndez-Vidal ^[4] ; Alvaro,Pinto ^[5] ; Ángel,Rodríguez ^[6] ; José Miguel,Cuevas Sanz ^[7] ; Jacobo Rodrigo,Muñoz Del Toro ^[8] ; Eduardo,Useros Rodríguez ^[8] ; Ángela,García García-Porrero ^[8] ; Sergio,Vázquez ^[9]

作者单位： Medical Oncology, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, C/Profesor Martín Lagos, s/n 28040, Madrid, Spain. javierpuente.hcsc@gmail.com. ^[1] Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. ^[2] Medical Oncology, ICO Girona, Hospital Josep Trueta, Girona, Spain. ^[3] Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC). Reina Sofía Hospital. University of Córdoba, Cordoba, Spain. ^[4] Medical Oncology, University Hospital La Paz - IdiPAZ, Madrid, Spain. ^[5] Medical Oncology, Hospital Universitario de León, León, Spain. ^[6] Medical Oncology, Hospital Universitario de la Ribera, Alcira, Spain. ^[7] Medical Department, Janssen-Cilag S.A., Madrid, Spain. ^[8] Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain. ^[9]

主题词腺癌(Adenocarcinoma);年龄因素(Age Factors);老年人(Aged);老年人, 80以上(Aged, 80 and over);贫血(Anemia);抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);虚弱(Asthenia);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);L-乳酸脱氢酶(L-Lactate Dehydrogenase);男(雄)性(Male);中年人(Middle Aged);多元分析(Multivariate Analysis);疼痛(Pain);泼尼松(Prednisone);比例危险度模型(Proportional Hazards Models);前瞻性研究(Prospective Studies);西班牙(Spain);紫杉烷类(Taxoids);治疗结果(Treatment Outcome)

DOI 10.1186/s12885-019-5974-9

PMID 31382926

发布时间 2024-07-19

检索历史清除

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).

BMC cancer

相似文献

BMC cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).

BMC cancer

相似文献

BMC cancer

相关期刊

检索历史清除